Owkin, a San Francisco-based AI company with $300 million in funding and a decade of experience, has unveiled a groundbreaking agentic infrastructure for biology at the JPM Healthcare Conference 2026. This new platform leverages AI agents trained on millions of multimodal datasets derived from real-world patient information collected across more than 800 hospitals globally over ten years. Unlike other AI systems focused primarily on lab-based data, Owkin’s approach centers on diverse, real-world clinical data, enabling more accurate and clinically relevant insights into human disease. The core innovation lies in its agentic architecture—autonomous AI agents capable of performing complex biomedical tasks such as biomarker discovery, interpreting multi-source datasets, and supporting clinical trial design. These agents operate while preserving patient privacy through advanced data governance, ensuring compliance with regulatory standards. The infrastructure is designed to integrate seamlessly with existing platforms, serving researchers, clinicians, and pharmaceutical developers across the healthcare ecosystem. A key milestone in this launch is Owkin’s strategic integration with Claude for Healthcare and Life Sciences (HCLS), Anthropic’s specialized AI platform. This partnership enables the deployment of Owkin’s AI agents—starting with Pathology Explorer—directly within Claude’s environment. Pathology Explorer, built on Owkin’s HIPE (Histo Interpretability Prediction Engine) model, achieves 23.7% higher classification accuracy than prior systems while using five times fewer parameters. It reduces computational time from weeks to hours, significantly accelerating pathology analysis and research workflows. Owkin’s vision extends beyond current tools. The company is pursuing the long-term goal of Biological Artificial Super Intelligence (BASI)—an AI system capable of reasoning across the full complexity of biological systems. This would allow the AI to not only analyze data but also generate new scientific hypotheses, design experiments, and discover novel treatments and diagnostics. At the heart of this vision is Owkin K, an AI copilot, and OwkinZero, a biology-tuned large language model that empowers scientists to validate hypotheses and accelerate drug development. The agentic infrastructure is the central connector between patient data from hospitals, research labs, and academic institutions and the pharmaceutical industry. By automating scientific discovery, Owkin aims to reduce the high failure rates of clinical trials and shorten the timeline from research to patient treatment. Thomas Clozel, M.D., co-founder and CEO of Owkin, emphasized that this marks a fundamental shift in how AI can drive biomedical innovation. “Our AI scientist will eventually understand causal biology, enabling it to create new therapies and diagnostics,” he said. The company’s approach combines domain expertise, curated multimodal data, and partnerships with leading AI firms like Anthropic to deliver tangible impact at scale. With Pathology Explorer now launching at JPM Healthcare Conference 2026, Owkin is setting a new standard for AI in healthcare. Its platform not only enhances research efficiency but also promotes responsible, privacy-preserving innovation. As AI continues to reshape medicine, Owkin’s agentic infrastructure stands as a pivotal step toward realizing the promise of intelligent, biology-driven discovery.